Sequenom unloads Bioscience business for $31M

Sequenom ($SQNM) sold off its Bioscience business to Agena Bioscience for $31 million. Through the deal, Agena gains access to Sequenom's MassArray System, a diagnostic tool that uses mass spectrometry to detect genetic biomarkers for cancer. Sequenom will receive up to $4 million in additional payments if MassArray meets certain regulatory and sales milestones, the company said in a statement. More

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.